Central GLP-1Rs distributed across the brain are predicted to mediate the anorectic and illness-like effects that accompany the therapeutic benefits of GLP-1–based analogs used for the treatment of diabetes and obesity. The gene discussed is GLP1R; the disease is obesity disorder.